Eric Aboagye is Professor of Cancer Pharmacology & Molecular Imaging and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He joined the college after a PhD at the CRUK Beatson Laboratories in Glasgow, UK and post-doc fellowship at The Johns Hopkins University & Hospital in Baltimore, USA. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.
Professor Aboagye was recipient of the 2009 Sir Mackenzie Davidson Medal and was elected as a Fellow of the Academy of Medical Sciences in 2010. Academy Fellows are elected for outstanding contributions to the advancement of medical science, for innovative application of scientific knowledge or for conspicuous service to healthcare.
et al., 2020, Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression, Journal for Immunotherapy of Cancer, ISSN:2051-1426
et al., 2020, Use of radioiodine in nuclear medicine-A brief overview., J Labelled Comp Radiopharm
et al., 2020, Clinical translation of 18F-fluoropivalate – a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers, European Journal of Nuclear Medicine and Molecular Imaging, Vol:47, ISSN:1619-7070, Pages:2549-2561
et al., 2020, Direct incorporation of [ 18F] into aliphatic systems: A promising Mncatalysed labelling technique for PET imaging., Curr Radiopharm
Witney TH, Fortt R, Aboagye EO, 2020, Preclinical assessment of carboplatin treatment efficacy in lung cancer by F-18-ICMT-11-positron emission tomography (vol 9, e91694, 2014), Plos One, Vol:15, ISSN:1932-6203, Pages:1-2